Just because a drug changes something measurable in your body (like a blood number) doesn’t mean it actually helps you feel better, live longer, or function better—you need proof it improves real-life outcomes.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
This claim reflects a well-established regulatory and clinical trial principle (e.g., FDA, EMA guidelines) that biomarkers are surrogate endpoints and must be validated against patient-centered outcomes to demonstrate true clinical benefit. Many drugs have shown biomarker improvement without translating to real-world benefit (e.g., CETP inhibitors, some cancer drugs). The use of 'cannot be established solely' is precise and avoids overstatement—it acknowledges biomarkers may be useful but insufficient alone. The claim is scientifically sound and aligns with current evidence-based practice.
More Accurate Statement
“Clinical benefit in human patients cannot be established based solely on biomarker modulation; regulatory approval and clinical adoption require direct evidence of improved patient-centered outcomes such as overall survival, functional status, or symptom burden.”
Context Details
Domain
medicine
Population
human
Subject
Clinical benefit
Action
cannot be established solely on
Target
biomarker modulation; proof of improved patient-centered outcomes is required
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
No evidence studies found yet.